Company news

Kala Bio, Inc. (NASDAQ:KALA) news

Kala Bio, Inc. news releases on 6ix. Latest, Sep 29, 2026: KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48…

Kala Bio, Inc. (NASDAQ:KALA) news

Press releases & updates

KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception

KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team

Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

KALA BIO Announces Reverse Stock Split

Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

KALA BIO Settles Approximately $10.6 million of Debt

KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint

KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference

KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

KALA BIO to Present at Jefferies Global Healthcare Conference

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

KALA BIO Announces Chief Executive Officer Transition

KALA BIO Announces $10,750,000 Private Placement

KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO Announces $12,500,000 Private Placement

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Kala Pharmaceuticals Announces Name Change to KALA BIO

KALA BIO to Participate in Upcoming Investor Conferences in August

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect

Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor